![](/img/cover-not-exists.png)
PCN99 COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE
Ouagari K El, V Pawar, J Coombs, J RubinVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)71994-5
File:
PDF, 76 KB
english, 2010